頁籤選單縮合
題名 | Olaparib治療復發性卵巢癌的檢視=The Role in the Treatment of Women with Recurrent Ovarian Cancer |
---|---|
作 者 | 李耀泰; 陳福民; 郭宗正; | 書刊名 | 婦癌醫學期刊 |
卷期 | 48 2018.10[民107.10] |
頁次 | 頁27-31 |
分類號 | 418.31 |
關鍵詞 | Poly (ADP-ribose) polymerase抑制劑; 復發性卵巢癌; Poly(ADP-ribose) polymerase inhibitor; PARPi; Olaparib; Recurrent ovarian cancer; |
語文 | 中文(Chinese) |
中文摘要 | 高度分化漿液性卵巢癌(high grade serous ovarian cancer, HGSOC)多因BRCA1和BRCA2基因突變所造成,估計約50%高度分化漿液性癌有同源重組的缺陷(homologous recombination deficiency, HRD),故對具同源重組的缺陷之患者可予poly(ADP-ribose)polymerase抑制劑(PARPi)來治療。現階段已證明,採olaparib治療高度分化漿液性卵巢癌,有較長的無症狀生存時間,特別是在BRCA1/2突變的患者,效果更加顯著。2014年12月,FDA通過olaparib可用在已使用過三線化學藥物及遺傳性突變卵巢癌。 |
英文摘要 | Germline mutation of BRCA1 and BRCA2 genes is often present in high-grade serous ovarian cancer (HGSOC). It has been estimated that approximately 50% of HGSOC tumors have homologous recombination deficiency (HRD). Targeting HRD with poly(ADP-ribose) polymerase inhibitor (PARPi) such as olaparib, in BRCA1/2 mutation and platinum sensitive HGSOC is an important therapeutic approach. Olaparib has anti-tumor activity and can be used as single agent therapy. Olaparib offers an effective maintenance treatment in recurrent, platinum-sensitive HGSOG, and its greatest benefits are demonstrated in women with BRCA1/2 mutation. FDA announced in December 2018 approved the use of olaparib as a monotherapy for germline BRCA mutated ovarian cancer after the third-line therapy. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。